UBS upgraded Medtronic (NYSE:MDT) to a Buy from Neutral today, telling investors in a research note that a “turnaround” is underway at the company. The upgrade raises an important question for investors: Is Medtronic finally returning to sustainable growth after years of underperformance, or is it too early to call the turnaround complete?
Bull case
One of the most prominent factors supporting Medtronic’s (NYSE:MDT) turnaround story is the company’s reporting of its highest annual revenue growth in 10 years in its fiscal Q4 and full-year 2026 results. Q4 revenue reached $9.8 billion, up 9.9% as reported and 6.6% organic, and FY 26 revenue was $36.4 billion, adjusted revenue of $36.3 billion, up 8.4% as reported and 5.8% organic. The trends suggest that the company is exhibiting continued operational rigor and building momentum in its highest growth opportunities, including Affera, Symplicity, Hugo, Altaviva, and Stealth AXiS.
Furthermore, Medtronic’s (NYSE:MDT) cardiac segment is emerging as one of the most prominent growth drivers for the company, as the Cardiac Ablation Solutions revenue rose 78% globally, including 124% U.S. growth. Several of the company’s newer product launches are beginning to contribute meaningfully to growth, helping strengthen its competitive position in several high-growth markets. It is also heavily investing in innovation and M&A, along with targeted investments in high-growth segments such as ICE catheter technology.
Another positive sign for investors is the considerable progress Medtronic (NYSE:MDT) has made in its high-growth platforms, including Symplicity Spyral for hypertension, now annualizing at $100 million. The company may also benefit from improving sentiment across the broader MedTech sector. BTIG recently noted in its research note previewing Q2 results in the sector that MedTech appears to be stabilizing following a period of underperformance. The firm believes that this stabilization is consistent with the overall market breadth expansion and broader momentum unwinding away from Semis/AI. While earnings cannot be considered a cure-all, they could serve as a catalyst for sentiment improvement, according to BTIG. This holds especially true if the sector can exhibit relative utilization strength and execution in a dynamic macro-environment.
Bear Case
However, investors may want to wait for several more quarters of consistent execution before concluding that Medtronic’s (NYSE:MDT) turnaround is complete. Management has spent several years attempting to accelerate growth, and the company’s recent momentum still needs to prove sustainable across multiple quarters.
